マルコ　イチロウ   丸子　一朗    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study.
掲載誌名	正式名：Japanese journal of ophthalmology 略　 称：Jpn J Ophthalmol ISSNコード：16132246/00215155
掲載区分	国外
巻・号・頁	66(4),pp.379-385
著者・共著者	Tanaka Koji, Koizumi Hideki, Tamashiro Tamaki, Itagaki Kanako, Nakayama Makiko, Maruko Ichiro, Wakugawa Sorako, Terao Nobuhiro, Onoe Hajime, Wakatsuki Yu, Kasai Akihito, Ogasawara Masashi, Shintake Hiroaki, Sugano Yukinori, Yamamoto Akiko, Kataoka Keiko, Hasegawa Taiji, Izumi Takahiko, Kawai Moeko, Maruko Ruka, Sekiryu Tetsuju, Okada Annabelle A, Iida Tomohiro, Mori Ryusaburo
発行年月	2022/07
概要	PURPOSE:To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (AMD) in a Japanese multicenter study.STUDY DESIGN:Retrospective case control study METHODS: The subjects were 58 eyes of 57 patients with neovascular AMD (43 men and 14 women, mean age 74.6 years) of whom 43 eyes of 42 patients completed initial loading of 3 monthly IVBr injections and were followed for more than 3 months. Best-corrected visual acuity (BCVA) changes, anatomical outcomes, and complications were investigated.RESULTS:Of the 43 eyes that completed loading doses, the AMD subtype was type 1 and type 2 macular neovascularization (MNV) in 51%, polypoidal choroidal vasculopathy (PCV) in 42%, and type 3 MNV in 7%. At 3 months after initiating treatment, BCVA significantly improved (P = 0.002) and central retinal thickness significantly decreased (P < 0.0001). At 3 months, complete retinal and subretinal fluid resolution was achieved in 91% of all eyes and complete regression of polypoidal lesions was achieved in 82% of PCV eyes. Iritis occurred in 8 eyes of 8 patients (14%), but resolved using topical or subtenon corticosteroid injection without visual loss in all cases.CONCLUSIONS:IVBr for treatment-naïve neovascular AMD was effective in the short-term, achieving significantly improved BCVA, good retinal fluid resolution, and a high rate of polypoidal lesion regression. However, iritis was noted in 14% of patients which may limit use of this drug.
DOI	10.1007/s10384-022-00922-3
PMID	35595951